Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Dr Antoine Chevalier Awarded Bronze Medal by Sons of the American Revolution for Devoted Service Aiding Homeless Suicidal Veterans


Dr. Antoine Chevalier Awarded Bronze Medal from Sons of the American Revolution

Dr. Antoine Cheavlier Awarded Bronze Medal from Sons of the American Revolution

Dr. Antoine Chevalier, PhD. H.P., L.M.T., M.P.P. Functional Medicine Practitioner & Advisor to the Executive Officer of the President, was awarded the prestigious Bronze Citizenship Medal by the legacy foundation Sons of the American Revolution George Washington Chapter. The Sons of the American Revolution gives only gold and bronze medals. The last recipient of the Gold Medal was ex Supreme Court Justice, Anthony Scalia. The award was given to Dr. Chevalier, for:


  • Treating more than 400 Veterans, mostly homeless, and athletes suffering from suicidal ideation due to the effects of concussion (post-traumatic stress disorder (PTSD), major depression disorder, traumatic brain injury (TBI), opioid addiction, chronic pain, and insomnia)
  • Providing services free of charge for those who cannot afford treatment
  • Demonstrating that his Functional Medicine Protocols increase neural plasticity and connectivity more than 70% with long-lasting results after one session

Non-members of the American Sons of the Revolution who have demonstrated service to the community in a manner that supports the objects of the society is required for consideration of the award; supporting Veterans of the U.S. Armed Forces is recognized by the organization.

To further his work with Veterans and professional athletes suffering the effects of concussion, Dr. Chevalier is establishing a global body of public research for brain injury therapy. For additional details on how to participate in the research study, visit https://urthecure.com To join Dr. Chevalier’s global research efforts in support of individuals who cannot afford therapeutic services, visit gofundme.

ABOUT DR. ANTOINE CHEVALIER, PhD, H.P., L.M.T., M.P.P.

Dr. Antoine Chevalier, also known as “The White House Doc”, is currently working with homeless military Veterans who have been clinically diagnosed suicidal, individuals battling depression, PTSD, gang members, children with Autism, patients who are visually impaired, professional athletes including NFL and NHL players, MMA fighters who are suffering from concussion tremors, and more. Dr. Chevalier’s therapy recommendations include healing botanicals that are tailored to a person’s unique biology. Dr. Chevalier’s hands-on experience has resulted in a wealth of world research results on addressing brain injury with natural botanicals and leading-edge technology.

Dr. Chevalier is establishing a non-profit organization, U R The Cure, to expand brain injury therapy research services nationally. Alliances and supporters of Dr. Chevalier include David Benhoff Lt. Col/USMC (Retired), Dr. Atsuhisa Nakano, MD, PhD, Dr. Aya Nakano, MD, PhD, C. Norman Shealy, M.D., PhD, professional athletes Marvin Washington, Daniel Puder, Lorenzo Neal, and actor Richard Dreyfuss. For additional details, visit https://urthecure.com

Share article on social media or email:

Introducing the Charm Myco Case for Portable Mycotoxin Testing


Charm Myco Case

The Charm Myco Case allows for on-the-go testing at a satellite facility, rail yard, or on a harvester in the field.

Charm Sciences, Inc., is pleased to introduce the Charm Myco Case, which makes it easy to run any of Charm’s mycotoxin tests from any location, with little setup. The customizable Myco Case neatly holds everything needed to run Charm’s trusted Rapid One Step Assay (ROSA®) mycotoxin tests: a Charm EZ®-M system, ROSA Quad Incubator, printer, Bluetooth Adapter, centrifuge, pipettes, graduated cylinder, and all disposable supplies needed to run the test.

“The Charm Myco Case allows for on-the-go testing at a satellite facility, rail yard, or on a harvester in the field,” said Karen Carmichael, Territory Account Manager at Charm Sciences. “The data, including the results and GPS coordinates, can be sent using the Bluetooth adapter to a centralized office via a smartphone. Combining this versatile testing system with Charm Science’s water-based extraction technology makes mycotoxin testing even simpler and more user-friendly by providing actual values for real-time decision making.”

Charm’s ROSA tests are available to detect aflatoxin, DON (vomitoxin), fumonisin, ochratoxin, T-2/HT-2 toxins, and zearalenone. The tests utilize Charm’s patented lateral flow technology to rapidly provide quantitative results, and they can all be read and recorded using the all-in-one Charm EZ-M system.

About Charm Sciences, Inc.

Established in 1978 in Greater Boston, Charm Sciences helps protect consumers, manufacturers, and global brands from a variety of issues through the development of food safety, water quality, and environmental diagnostic tests and equipment. Selling directly and through its network of distributors, Charm’s products serve the dairy, feed and grain, food and beverage, water, healthcare, environmental, and industrial markets in more than 100 countries around the globe. https://www.charm.com

© 2020 Charm Sciences, Inc. Charm, Charm EZ, and ROSA are registered trademarks of Charm Sciences, Inc.

Share article on social media or email:

Rare Disease Drug Launch – Lessons Learned to Ensure Success is Not a Rare Event, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

This webinar will focus on key challenge areas and critical success factors in rare disease launch readiness including accurate opportunity sizing, engaging advocates, managing accelerated review timelines and access challenges.

Rare disease drug launches are more common than ever. Commercial teams will continue to need rare disease drug launch expertise, as over a third of industry R&D pipeline are orphan drugs. Preparing for a rare disease drug launch is more challenging than ever before with increased competition, price pressures, and customer expectations. Success in rare disease drug launch depends on early preparation, tailored strategy, and an exquisite understanding of and responsiveness to customer needs.

With a $131 billion market valuation and 11% growth rate, it’s clear why rare disease product launch has increased. Commercial attractiveness of rare disease drug launches stems from high price points, increased exclusivity and R&D tax and cost benefits. Orphan drug designation enables 7-10-year market exclusivity and an asset can hold orphan designations across several indications.

This webinar will focus on key challenge areas and critical success factors in rare disease launch readiness including accurate opportunity sizing, engaging advocates, managing accelerated review timelines and access challenges. Our industry and professional services speakers will share lessons learned from real examples of rare disease launch readiness efforts.

Join Beth Schurman, Partner, Herspiegel Consulting and Jennifer Beachell, Vice President Commercial, Momenta Pharmaceuticals in a live webinar on Friday, October 9, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Rare Disease Drug Launch – Lessons Learned to Ensure Success is Not a Rare Event.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

You May Be Able to Reduce Your Risk of Dementia, According to New Study


News Image

Simply wearing a hearing aid may help reduce the risk of developing the devastating condition, according to the review, led by Prof Gill Livingston of University College London.

The latest research report from The Lancet Commission on Dementia Prevention, Intervention and Care, released on July 30, 2020, shows that modifying 12 risk factors from childhood to late life could delay or prevent 40% of dementia cases. Of these 12, an untreated hearing loss in midlife remains the largest modifiable risk factor.1 The study also cites that, “hearing loss might result in cognitive decline through reduced cognitive stimulation”.2 In times of social distancing, people who isolate themselves should be aware of increased dementia risks. Untreated hearing loss has been known to lead to social isolation.3 Chief Audiologist for HearingLife, Dr. Leslie Soiles, recommends hearing aids to those with hearing loss as a means of maintaining an active lifestyle – and possibly reducing one’s risk for developing dementia.

Fifty million people are living with dementia worldwide.1 Individuals with mild hearing loss have double the dementia risk, those with moderate hearing loss have triple the risk, and those with severe hearing impairment have an increased dementia risk of up to 5 times that of those who do not have a hearing impairment, according to the National Institute of Health.1 A US nationally representative survey of 2,040 people older than 50, tested every two years for 18 years, found immediate and delayed recall deteriorated less after initiation of hearing aid use, adjusting for other risk factors.3 “Hearing aid use was the largest factor protecting from decline adjusting for protective and harmful factors.”3

As communicated in the 2020 Lancet report, there are lifestyle factors that can be adjusted in order to help reduce one’s risk for developing dementia. The 12 modifiable risk factors identified in the report are: hearing impairment, education, hypertension, smoking, obesity, depression, physical inactivity, diabetes, low social contact, excessive alcohol consumption, brain injury and air pollution. With hearing loss being the largest modifiable risk factor in protecting from cognitive decline.3

Receiving regularly scheduled hearing tests is a preventative measure for maintaining a healthy level of hearing. Even for those who are not experiencing hearing loss symptoms, getting an annual hearing test is recommended by hearing care experts as part of leading a healthy lifestyle. 3 HearingLife, has more than 600 locations nationwide and offers complimentary hearing assessments, as well as a risk-free hearing aid trial for new hearing aid users. HearingLife’s mission is to help more people hear better by providing personalized, professional care tailored to their individual needs. Helping people reach their full hearing potential may lead to living a better quality of life, staying more active, and helping to prevent the risks of untreated hearing loss, which include isolation, depression and dementia.

Do you know someone who may have hearing loss? “Hearing loss can be hard to identify when one first begins to notice symptoms,” shares Dr. Soiles. “With hearing loss and dementia being two global health issues that are on the rise, it is increasingly important that those who think they have hearing loss get their hearing checked by a hearing care expert.” Early adoption of hearing aids for those who have hearing loss may lead to an overall higher quality of life and may help protect against the development of dementia.

As a part of their initiative to provide life-changing hearing care, HearingLife presents The Campaign for Better Hearing which informs and educates people about hearing health and the consequences of untreated hearing loss. To date, the campaign has conducted over 450,000 hearing screenings and has raised over $1.7 million which is used to provide hearing aids to those in need through the campaign’s “Give-Back Program.” Every new hearing screening and hearing aid fitting is a chance to help reduce someone’s dementia risk. 3

-ENDS

ABOUT HEARINGLIFE

HearingLife is a Demant company, a world-leading hearing healthcare group, that was founded on care. We have a long history of making life-changing differences through hearing health. HearingLife is one of the largest groups of hearing care centers in the U.S. with more than 600 centers nationwide across 42 states. We follow a proven, results-oriented approach to hearing health where skilled professionals deliver the best hearing care, tailored to the unique needs of each customer.

1 Source https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075051/

2 Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075051/

3 G Livingston, Jonathan Huntley, Andrew Sommerlad, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. July 30, 2020.

Share article on social media or email:

Agri-Neo places on The Globe and Mail’s second-annual ranking of Canada’s Top Growing Companies


We are thrilled and honored to have our accomplishments recognized by The Globe and Mail. This achievement goes out to our employees and our customers for their commitment to food safety and consumer protection.”

Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Agri-Neo earned its spot with three-year growth of 308%.

Agri-Neo is a technology company focused on developing food safety solutions for a wide range foods. Its patented organic pasteurization technology, Neo-Pure, provides a 5-log (99.999%) reduction of harmful pathogens such as Salmonella, E. coli, and Listeria, while maintaining the raw nutrition and sensory qualities of foods such as nuts, seeds, and grains. Agri-Neo has also recently launched Neo-Temper, an organic food safety solution for flour, to address the growing number of flour recalls in North America. In the future, Agri-Neo plans to develop more food safety solutions for fruits & vegetables, meats, and other food groups with high risk of food safety recalls.

“We are thrilled and honored to have our accomplishments recognized by The Globe and Mail. This achievement goes out to our employees and our customers for their commitment to food safety and consumer protection,” said Nick Dillon, CEO of Agri-Neo. “We are proud to provide solutions to food safety problems, and will continue to advance our mission of helping safely feed the world. Every year, over 600 million people around the world fall ill after eating contaminated food and we want to help eliminate this global problem.”

Launched in 2019, the Canada’s Top Growing Companies editorial ranking aims to celebrate entrepreneurial achievement in Canada by identifying and amplifying the success of growth-minded, independent businesses in Canada. It is a voluntary program; companies had to complete an in-depth application process in order to qualify. In total, 400 companies earned a spot on this year’s ranking.

The full list of 2020 winners, and accompanying editorial coverage, is published in the October issue of Report on Business magazine—out now—and online at tgam.ca/TopGrowing.

“The stories of Canada’s Top Growing Companies are worth telling at any time, but are especially relevant in the wake of COVID-19 pandemic,” says James Cowan, Editor of Report on Business magazine. “As businesses work to rebuild the economy, their resilience and innovation make for essential reading.”

“Any business leader seeking inspiration should look no further than the 400 businesses on this year’s Report on Business ranking of Canada’s Top Growing Companies,” says Phillip Crawley, Publisher and CEO of The Globe and Mail. “Their growth helps to make Canada a better place, and we are proud to bring their stories to our readers.”

About The Globe and Mail

The Globe and Mail is Canada’s foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 5.9 million readers every week in print or digital formats, and Report on Business magazine reaches 2.1 million readers in print and digital every issue. The Globe and Mail’s investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.

About Agri-Neo

The Agri-Neo mission is to help safely feed the world by creating technology that sets new food safety standards. Neo-Pure™ and Neo-Temper™ developed by Agri-Neo, eliminate harmful pathogens such as Salmonella, E. coli, and Listeria, while maintaining the nutrition and quality that flourishes naturally in food. Agri-Neo has a dedicated team of food scientists, researchers, and engineers to launch more food safety solutions for many high risk food groups in the future. For more information, visit http://www.agri-neo.com.

Share article on social media or email:

South Broward Hospital District Reduces Taxpayer Millage Rate Despite Increased COVID-19 and Uncompensated Care Expenses


Memorial Healthcare System is one of the largest public healthcare systems in the U.S. and a national leader in quality care and patient satisfaction.

“These are unprecedented times for our healthcare system and our community, and we continue to face and manage many challenges. Given Memorial’s outstanding leadership and sound financial stewardship, we felt confident to pass on these savings to the communities we serve.”

The Board of Commissioners of the South Broward Hospital District, which oversees the operations for Memorial Healthcare System, voted on a new millage rate during its September board meeting. The Board voted to adopt a millage rate of 0.1199.

This is the tenth year in a row that the Board has voted to lower the overall millage rate for the District with 0.1199 resulting in the lowest rate in the history of the South Broward Hospital District. The 0.1199 millage rate represents a 4.84 percent decrease from last year’s rate of 0.1260. The resulting gross tax revenues are estimated to reach $7.8 million.

“These are unprecedented times for our healthcare system and our community, and we continue to face and manage many challenges. Given Memorial’s outstanding leadership and sound financial stewardship, we felt confident to pass on these savings to the communities we serve,” said Douglas Harrison, Chairman, South Broward Hospital District Board of Commissioners.

After accounting for early payment discounts and a certain percentage of uncollectible taxes, the anticipated tax payments this year of $7.6 million will provide the District enough revenue to cover its governmental obligations, which include paying Broward County’s Medicaid Match program and community redevelopment agencies in several municipalities in south Broward County, as well as tax collector commissions and property appraiser fees.

The newly adopted millage rate will leave no net tax revenue to fund uncompensated care. The District will use operating income to cover all uncompensated care costs for the entire Memorial Healthcare System, including its six hospitals and its nine Memorial Primary Care clinics. In fiscal year 2021, uncompensated care is projected to exceed $1.6 billion.

This historic reduction comes at a time when Memorial Healthcare System has responded with excellence, dedication and leadership to the COVID-19 pandemic and the community it serves, providing life-saving care to thousands of patients while keeping its frontline workforce safe. In addition, it continues to train the doctors and nurses of the future. The Graduate Medical Education Program has now an expanded list of 12 residencies, including two fellowship programs in cardiovascular disease and hematology and medical oncology.

On the technological front, Memorial expanded access to care through telehealth consults from primary to specialty care to maintain continuity of care during physical restriction periods due to the pandemic. It has added new tools to Memorial MyChart, and continues its successful “Your Right to Know” initiative – providing consumers with an Amazon-like experience in obtaining medical procedure pricing information. Memorial also remains one of only a handful of public hospitals in the nation to achieve AA, Aa3 financial ratings by Standard and Poor’s and Moody’s, respectively.

“We have an amazing leadership team,” said Aurelio M. Fernandez, III, President and CEO, Memorial Healthcare System. “This team has been very responsive throughout the COVID pandemic, while working diligently to maintain a sound financial structure that allow us to reduce the millage rate to the lowest one in the history of our organization.”

Memorial Healthcare System is one of the largest public healthcare systems in the country and a national leader in quality care and patient satisfaction. Its facilities include Memorial Regional Hospital, Memorial Regional Hospital South, Joe DiMaggio Children’s Hospital, Memorial Hospital West, Memorial Hospital Miramar, Memorial Hospital Pembroke and Memorial Manor nursing home.

The system received the following recognitions: Modern Healthcare magazine’s “Best Place to Work in Healthcare,” Florida Trend’s “Florida’s Best Companies to Work For,” and Becker’s Hospital Review’s “150 Great Places to Work in Healthcare.”

For more information, visit mhs.net.

Share article on social media or email:

Facial Plastic Surgeon Introduces Revolutionizing and Innovative Facial Contouring Combination With Buccal Fat Removal & Sculpting


buccal fat removal chicago - dr benjamin caughlin

This innovative, new procedure outlines the esteemed surgeon’s constant development to provide his patients with ways to achieve their desired look. By offering his treatment plan that he calls “Cheekago”, which is a balanced 4-layer cheek sculpting procedure, it propels Dr. Caughlin into a class of his own, making him the only plastic surgeon in the United States to provide this cutting edge treatment.

“Cheekago” is a procedure that tightens and contours all four layers of the cheek to help patients achieve a perfectly balanced and defined result that other surgeons across the globe struggle to provide. Note that some patients get 1 layer tightened, some 3, and others the full 4 layers. The key to this procedure is that it is customized to the unique patient. The four layers consist of Buccal Fat Pad Removal or Buccal Fat Pad Sculpting, Internal Cheek Mucosal Tightening, Buccinator Muscle Narrowing, and Precisely Placed Calcium Hydroxyapatite and/or liposculpting of the jawline. Each stage of this treatment is individually designed to produce a sharper, distinct and contoured look. Tightening and sculpting each of these areas of the face allows Dr. Caughlin to deliver the look people are after, by harnessing peaks and valleys in order to create attractive shadows and curves.

Creating a defined look (often referred to as a “#snatched look” on social sites where selfies are prominent) that patients can feel confident and be proud of is something that Dr. Caughlin strives for every day. Anyone in search of sculpting and defining their cheeks and jawline or having a sharper look makes them the ideal candidate for this revolutionary procedure.

Dr. Caughlin is highly dedicated to providing the best for his patients by welcoming them in an inviting and state-of-the-art surgical clinic in downtown Chicago, listening to what the patients want, and creating a patient-focused plan for optimal satisfaction. To inspire future patients, Dr. Caughlin invites others to see results firsthand by following the hashtags #GetSnatched and #ManyFacesOfChicago on Instagram or visiting his website at DrBuccalfat.com.

Dr. Benjamin Caughlin is a facial plastic surgeon working at 845 N Michigan Ave #923e Chicago, IL 60611. Led by Dr. Caughlin, each unique patient has the choice from an array of facial contouring options that provide stunning appearances. You can learn more about Dr. Caughlin’s popular Buccal Fat Removal and other Face Sculpting procedures on his website DrBuccalFat.com, and you can also see more of the life-changing work he has done for past patients on his Instagram @ManyFacesOfChicago.

Share article on social media or email:



Applications of Liver Humanized Mouse Models in Preclinical Drug Development, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

Over the past two decades, much progress has been made in the development of mouse models which are able to achieve at least 70% replacement of mouse hepatocytes with human hepatocytes.

Animal models are traditionally used in the drug development process to determine the safety and efficacy of new drug candidates. Yet, translation between animals and humans is not always straightforward due to inherent differences between species. A promising way to bridge this gap has been the development of chimeric mice possessing humanized livers. Over the past two decades, much progress has been made in the development of mouse models which are able to achieve at least 70% replacement of mouse hepatocytes with human hepatocytes. This has enabled the use of these models for an increasing variety of applications in the preclinical drug development process.

The first segment of this webinar will focus on the genetic basis of these liver-humanized mouse models, as well as their historical development and characterization. The second and major segment of the presentation will illustrate their use in a wide variety of in vivo and in vitro applications over the past decade. These include liver disease models such as hepatitis B and C virus infection. Numerous publications have described the use of liver-humanized mouse models for studies on drug metabolism and pharmacokinetics, enzyme induction, drug clearance projections, identification of human metabolites and the prediction of clinically relevant drug-drug interactions. Liver toxicity studies have been carried out both in vivo and in vitro, the latter utilizing hepatocytes isolated from these liver humanized mice. Finally, these models are useful to test the delivery of gene therapy reagents to the liver, as well as to repopulate the liver with genetically modified hepatocytes.

Join David Thompson, Ph.D., Sr. Director, Mechanistic Pharmacology & Toxicology, Inotiv in a live webinar on Thursday, October 15, 2020 at 1pm EDT.

For more information or to register for this event, visit Applications of Liver Humanized Mouse Models in Preclinical Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Saliva Study Breakthrough Discovered By Dr. David T.W. Wong On Sharon Kleyne Talk Radio


Sharon Kleyne, Founder of Bio Logic Aqua® Research

Sharon Kleyne, Founder of Bio Logic Aqua® Research

Air Date: 28th September 2020

Guest: Dr. David T.W. Wong, DMD, DMSC, Felix & Mildred Yip Distinguished Professor, Associate Dean of Research and Director of the Oral/Head and Neck Oncology Research Center at UCLA; Fellow of the American Association for the Advancement of Sciences (AAAS), Fellow of AADR, past member of the ADA Council of Scientific Affairs and past president of American Association of Dental Research (AADR); currently chair of the NCI Liquid Biopsy Consortium and chartered member and co-chair of the NIH CSR Cancer Biomarker Study Section (CBSS).

https://www.voiceamerica.com/episode/125933/saliva-diagnostics

Dr. David T. W. Wong of UCLA shares a major breakthrough in the testing and rapid identification of pathogens such as COVID-19 on Sharon Kleyne’s, internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist®, naturally pH balanced water technology for acid mantle protection, on VoiceAmerica World Talk Radio & Apple iTunes.

Born and raised in Asia, Wong moved to Vancouver, British Columbia, did graduate work Boston and had his residency at Harvard University before moving west to UCLA eighteen years ago. Wong has focused on cancer research and diagnostics from saliva.

Kleyne states that dentists need to do much more to educate their patients about their oral cavity and its connection to their immunity strength and weaknesses.

“The oral cavity is part of the body,” Wong says. “It communicates with the environment. Essential to every function such as mastication, speech and each body function is the production of saliva. There are three major saliva glands that collectively produce 600 millimeters of saliva on a daily basis. Saliva assists in digestion of food, aids capability of speech, and wards off pathogens. People with autoimmune problems don’t produce saliva; people exposed with radiation in the head and neck make less saliva.”

Wong describes how sixteen years ago the National Institute of Health invested in the scientific community and posed a question. It asked researchers to scientifically credential saliva, a non-evasive material produced by our body that could be utilized for early disease detection. “The entire world is seeking early detection in the most non-evasive way. During this pandemic, half of research funding has been for saliva,” says Wong.

Kleyne notes that there has been pushback against saliva research and compares it to her organ of the eye research. “That is similar to what happened with the organ of the eye. There was little research into dry eye and it’s taken years to educate people about the potential immunity weakness of the eye,” says Kleyne.

Wong praises Kleyne’s insightfulness. “The pushback has been significant, and partially rightly so, because the science wasn’t there. But now this pandemic has brought saliva research to the front line.” Wong also cites an important study at Tufts University.

A team of scientists, led by Jill L. Maron, MD. MPH. Associate Professor of Pediatrics at Tufts Medical Center, (https://www.tuftsmedicalcenter.org/PhysicianDirectory/Jill-Maron) have conducted the SPITSS study. The study reports that by combining gene amplification techniques with advanced computational analysis tools they were able to identify and validate salivary biomarkers to predict oral feeding readiness in preterm infants.  This biomarker panel is the first to address oral feeding readiness in the newborn. “The method being tested, if successful, could have several other benefits besides reducing antibiotic exposure in newborns. Hospitalizations could be shortened, saving tens of millions of dollars.  If successful, this approach may also allow doctors to better differentiate bacterial from viral infections, and more quickly prescribe the proper drugs to treat them.  For premature infants, their saliva profiles may help determine risk for other conditions associated with prematurity and inflammation, including lung and eye disease.”

Wong mentions a University of Michigan project that compared the protein that is in saliva and the protein in blood. The antibody in blood can also be found in saliva. So, we can now measure the antibodies in saliva. We are heading towards tests to be able to test everybody’s immunity through their saliva.

“The long-term goal is that in about three months a drop of saliva could concurrently and simultaneously evaluate if someone is infected with a virus as well as test immunity,” Wong announces.

“That is a major breakthrough,” says Kleyne. “People are so impatient with the testing during this pandemic. That’s why it’s so important to pay attention to the hygiene of the mouth.”

Wong agrees. “Looking at the oral cavity, per say, follow the advice of your dentists. Diligence and regularity are important. It’s a matter of brushing and flossing. The systemic health and your wellbeing are all factored into your oral health. The organ of the mouth reflects your systemic health. Every day, we produce a full soda can of saliva if we are healthy.”

“People also need to brush the tongue. Pathogens can thrive on the tongue.”

Wong points out that a University of Michigan project has compared the protein that is in saliva and the protein in blood. The antibody in blood can also be found in saliva. We can now measure the antibodies in saliva and we are heading towards a time when we will be able to test everybody’s immunity through their saliva.

“The portal entry of the pathogens to our bodies is the oral cavity and nasal cavity,” says Wong. “IGA antibodies exist in the mouth, offering protection, if you will. It is important to guard the portal entry to assist the mouth’s antibodies in fighting off pathogens such as the virus.”

“So, wearing a mask is good common sense,” says Kleyne.

If you care about immunity protection for the organ of the eyes, listen to these programs.

They feature wisdom, knowledge, new technology and health tips for better living every week on the internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist®, naturally pH balanced water technology for acid mantle protection on VoiceAmerica World Talk Radio & Apple iTunes with Program Director Rose Hong of Global Dragon TV with Sharon Kleyne.

LISTEN to the internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist®, naturally pH balanced water technology for acid mantel protection, on VoiceAmerica World Talk Radio & Apple iTunes with producer and host Sharon Kleyne and program director Rose Hong of Global Dragon TV. This program features Dr. David T. W. Wong.

Follow this link:

https://www.voiceamerica.com/episode/125933/saliva-diagnostics

Some recent Sharon Kleyne talk radio programs feature:

Nancy Yonally Coleman & James Derick https://www.voiceamerica.com/episode/125837/be-safe-strategies-for-you-and-your-families-to-go-back-to-school-and-work-safely-during-covid

Dr. David Clarke https://www.voiceamerica.com/episode/125671/hidden-stresses-and-your-health

Philip Paden, M.D. https://www.voiceamerica.com/episode/125579/encore-immunity-protector-with-natures-tears-eyemist

Kevin Kearns & Ken Baum https://www.voiceamerica.com/episode/125437/mental-strategies-how-to-cope-with-covid-and-transfer-your-life

Nancy Yonally Coleman https://www.voiceamerica.com/episode/125328/drug-addiction-and-its-impact-on-immune-system-and-mental-health-during-the-pandemic

If you would like to watch a brief, entertaining educational film that demonstrates the application of the new Dry Eye Solution® technology Nature’s Tears® EyeMist®, sponsor of Sharon Kleyne’s talk radio program, go here: https://www.youtube.com/watch?v=l0gOr8TB45U

NeoTract Designates Dr. Michael Rittenberg as UroLift® Center of Excellence


News Image

“Dr. Michael Rittenberg has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Michael Rittenberg, M.D., Riverview Urologic Associates in Kingston, PA, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Rittenberg has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Michael Rittenberg has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email: